Sort
21,453 grants matching “tuberculosis”
Malaria Transmission and the Impact of Control Efforts in Southern and Central Africa
$1,422,998William J Moss · Johns Hopkins University · U19 · FY2019 · AI
Stellenbosch University Clinical Trial Unit, Cape Town, South Africa
$1,422,798Mark Fredric Cotton · Stellenbosch University · U01 · FY2009 · AI
Addressing HyperteNsion and Diabetes through Community-Engaged Systems in Puno Peru (ANDES study)
$1,422,658Stella Maria Hartinger · Universidad Peruana Cayetano Heredia · UH3 · FY2023 · HL
MYCOBACTERIUM TUBERCULOSIS (MTB) QUALITY ASSESSMENT PROGRAM (TBQA)
$1,422,337Jeanette Coffin · Midwest Research Institute · N01 · FY2019 · AI
Response Therapies for MDR-TB
$1,421,958Ian M Orme · Colorado State University · U01 · FY2009 · AI
Vector-Borne Diseases: Biology Of Vector Host Relationship
$1,420,391Jose Ribeiro · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Malaria Transmission and the Impact of Control Efforts in Southern and Central Africa
$1,419,452William J Moss · Johns Hopkins University · U19 · FY2021 · AI
Sputum Transcriptomic Expression Profiling in Study 31: Express 31
$1,418,814Payam Nahid · University Of California, San Francisco · R01 · FY2020 · AI
RP3: Targeting ATG gene-dependent immunity for novel anti-infective therapeutics
$1,418,421Seungmin Hwang · Ut Southwestern Medical Center · U19 · FY2020 · AI
Malaria Transmission and the Impact of Control Efforts in Southern and Central Africa
$1,418,082William J Moss · Johns Hopkins University · U19 · FY2020 · AI
Malaria Transmission and the Impact of Control Efforts in Southern and Central Africa
$1,418,064William J Moss · Johns Hopkins University · U19 · FY2022 · AI
Malaria Transmission and the Impact of Control Efforts in Southern and Central Africa
$1,418,064William J Moss · Johns Hopkins University · U19 · FY2023 · AI
Immunoregulation /Immune Recognition In Filarial/Nonfilarial Parasitic Infection
$1,417,614Thomas Nutman · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
Human immune signatures of latent MTB infection, active disease and BCG vaccination
$1,417,299Bjoern Peters · La Jolla Institute For Immunology · U19 · FY2018 · AI
PS05-003, TUBERCULOSIS CONTROL PROGRAM AND AIDS
$1,416,344Jon Warkentin · Tennessee State Department Of Health · U52 · FY2009 · PS
PS05-003, TUBERCULOSIS CONTROL PROGRAM AND AIDS
$1,416,344Jon Warkentin · Tennessee State Department Of Health · U52 · FY2008 · PS
Integrated University of Puerto Rico Clinical Trials Unit
$1,416,111Carmen D Zorrilla · University Of Puerto Rico Med Sciences · UM1 · FY2019 · AI
San Francisco Bay Clinical Trials Unit (CTU)
$1,415,883Susan Buchbinder · Public Health Foundation Enterprises · UM1 · FY2024 · AI
Role of Inducible Bronchus Associated Lymphoid Tissue in Latent Tuberculosis
$1,415,724Shabaana A. Khader · University Of Chicago · R01 · FY2023 · AI
San Francisco Bay Clinical Trials Unit (CTU)
$1,415,682Susan Buchbinder · Public Health Foundation Enterprises · UM1 · FY2023 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis
$1,413,190Jerrold J. Ellner · Boston Medical Center · U19 · FY2018 · AI
Experimental Animal Models of TB: Chemotherapeutics and Imaging
$1,413,031Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
RP2: Targeting genes and pathways for autophagy-dependent inhibition of bacterial infection
$1,411,732Ramnik J Xavier · Ut Southwestern Medical Center · U19 · FY2023 · AI
The International URBAN Alcohol Research Collaboration on HIV/AIDS (ARCH) Center
$1,411,395Jeffrey H Samet · Boston Medical Center · P01 · FY2024 · AA
Childhood âOmicsâ and Mycobacterium tuberculosis-derived BiOsignatures (COMBO) for TB diagnosis in high HIV prevalence settings
$1,410,811Adithya Cattamanchi · University Of California-Irvine · R01 · FY2023 · AI